Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24

Park, Jinsung; Shin, Dong Wook; Kim, Tae-Hwan; Jung, Seung Il; Nam, Jong Kil; Park, Seung Chol; Hong, Sungwoo; Jung, Jae Hung; Kim, Hongwook; Kim, Won Tae

Bladder cancer (BC) is the second most common cancer of the genitourinary tract in Korea and worldwide [1, 2] . Urothelial carcinomas represent more than 90% of BC and are classified into non-muscle invasive BC (NMIBC) and muscle invasive BC according to depth of invasion. Majority of patients with BC are diagnosed with NMIBC [3] , and it is treated with transurethral resection of bladder tumor (TURBT) with/without intravesical treatment. However, despite complete removal of NMIBC by TURBT, significant proportions of patients undergo tumor recurrence ranging from 15% to 90% within 5 years [4] [5] [6] . In addition to frequent tumor recurrence, clinical practice (including regular cystoscopy follow-up and intravesical treatment) may be associated with various side effects and patient morbidity, which consequently result in decreased patient quality of life (QOL). Thus, reliable and valid measure of such patient QOL is becoming important assessment of clinical outcomes as the issues of disease-free and BC-specific survival and would form the basis for the research and development of better BC treatment methods [7] .